Trastuzumab Emtansine(Roche / Genentech)은 Metastatic Salivary Gland Carcinoma 표적 ADC로, HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting human epidermal growth factor receptor. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 69.3% (ClinicalTrials.gov NCT01120184). PK: t½ 4 h. 차별점: novel [ 225 Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
Metastatic Salivary Gland Carcinoma
HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer
Recruiting
ADCs) are constrained by limited tumor penetration of IgG forma
DM1 via butelase-1 with ABD fusion for pote
cleavable peptide linker and a topoisomerase I payload with byst
novel [ 225 Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer
targeting human epidermal growth factor receptor
antibody-dependent cell-mediated cytotoxicity
payload axis: a cleavable peptide linker and a topoisomerase I payload with bystander activity
HER2-positive
resistance mechanisms, including efflux pump overexpression, apoptotic pathway alterations, and adaptive survival signaling, contributing to
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Trastuzumab Emtansine(Roche / Genentech)은 Metastatic Salivary Gland Carcinoma 표적 ADC로, HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting human epidermal growth factor receptor. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 69.3% (ClinicalTrials.gov NCT01120184). PK: t½ 4 h. 차별점: novel [ 225 Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
Metastatic Salivary Gland Carcinoma
HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer
Recruiting
ADCs) are constrained by limited tumor penetration of IgG forma
DM1 via butelase-1 with ABD fusion for pote
cleavable peptide linker and a topoisomerase I payload with byst
novel [ 225 Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer
targeting human epidermal growth factor receptor
antibody-dependent cell-mediated cytotoxicity
payload axis: a cleavable peptide linker and a topoisomerase I payload with bystander activity
HER2-positive
resistance mechanisms, including efflux pump overexpression, apoptotic pathway alterations, and adaptive survival signaling, contributing to
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.